Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Biotechnologie”

17:45 · Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant · Persbericht

17:45 · Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant · Persbericht

15:05 · Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer · Persbericht

14:30 · Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 · Persbericht

14:00 · Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development · Persbericht

13:30 · FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy · Persbericht

12:00 · IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma · Persbericht

08:30 · NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer · Persbericht

28/03 · REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS · Persbericht

28/03 · Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity · Persbericht

28/03 · Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting · Persbericht

28/03 · ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 · Persbericht

28/03 · MREO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 · Persbericht

28/03 · Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology · Persbericht

28/03 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

28/03 · uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

27/03 · Scalable Biotech Manufacturing Unlocks a $14B Market · Persbericht

27/03 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27/03 · Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older · Persbericht

26/03 · DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document · Persbericht

26/03 · DBV Technologies Reports Full Year 2025 Financial Results and Business Update · Persbericht

Mijn selecties